Treatment of mice with IGF-I stimulates T and B cell development. We showed that overexpression of IGF-II in transgenic FVB/N mice only stimulated T cell development. In the present study, we further addressed the in vivo effects of IGF-II in the absence of IGF-I to get more insight into the potential abilities of IGF-II to influence T and B cell development. To this end, we studied lymphocyte development in IGF-II transgenic Snell dwarf mice that are prolactin, GH and thyroid-stimulating hormone deficient and as a consequence show low serum IGF-I levels. We showed that T cell development was stimulated to the same extent as in IGF-II transgenic FVB/N mice. Furthermore, IGF-II increased the number of nucleated bone marrow cells and the number of immature B cells without having an effect on the number of mature B cells in spleen and bone marrow. Our data show that IGF-II has preferential effects on T cell development compared with B development, and that these preferential effects also occur in the absence of measurable IGF-I levels.
Introduction
Insulin-like growth factor-I (IGF-I) is an important fetal and postnatal growth factor, whereas IGF-II has been implicated predominantly in fetal growth (DeChiara et al. 1990 , van Buul-Offers 1996 . The growth promoting effects of growth hormone (GH) are mediated by IGF-I which is mainly produced in liver but also by many other tissues ( Jones & Clemmons 1995) . Both GH and IGF-I have also been implicated in the development and function of the immune system (Hooghe-Peters & Hooghe 1995, Kooijman et al. 1996) . In leukocytes, IGF-I can be produced under the control of GH (Merimee et al. 1989 , Baxter et al. 1991 and several cytokines (Kirstein et al. 1992 , Arkins et al. 1995 . Furthermore, it has been demonstrated that IGF-I stimulates the development of lymphocytes (Hooghe-Peters & Hooghe 1995) . IGF-I augments the in vitro proliferation of thymocytes (Kooijman et al. 1995a,b) and pro-B cells (Gibson et al. 1993) , and it induces pro-B cell differentiation (Landreth et al. 1992) . Furthermore, overexpression of IGF-I in mice stimulates T and B cell development (Clark et al. 1993) and antigen specific IgG synthesis (Robbins et al. 1994) .
Since IGF-II is expressed in the epithelial cells of the thymus of adult rats and humans (Geenen et al. 1993) , and IGF-II overexpression in transgenic mice leads to a selective effect on thymic growth (van Buul-Offers et al. 1995) , we investigated the effects of IGF-II on T cell development. Using two lines of transgenic mice that overexpress IGF-II in spleen, thymus and serum, we demonstrated that IGF-II stimulates the development of phenotypically normal T cells but has no effect on the development of mature B cells (Kooijman et al. 1995b) .
The cellular effects of IGF-I are mediated by the type I IGF receptor. In most cell types the effects of IGF-II are also mediated by the type I IGF receptor to which IGF-II binds with a 2-to 10-fold lower affinity than IGF-I. However, in certain cell types the effects of IGF-II have been shown to be mediated by its own receptor (type II IGF receptor). Due to the fact that IGF-II can bind to type I IGF receptors, it is possible that the role of IGF-II on T and B cell development will not become clear in an overexpression model for IGF-II in mice with normal IGF-I levels. In this paper we further address the in vivo effects of IGF-II in the absence of IGF-I to get more insight into the potential abilities of IGF-II to influence T and B cell development. To this end, we used IGF-II transgenic dwarf mice that were obtained by intercrossing transgenic FVB/N mice with Snell dwarf mice. The Snell dwarf mouse has a mutation (dw) in the POU-homeodomain of Pit-1 transcription factor for GH, prolactin and thyroid-stimulating hormone (Li et al. 1990) . As a consequence, the dwarf mice are GH and IGF-I deficient and show a moderately reduced number of thymocytes and a severe reduction in the number of splenocytes (Kelley 1989) . Murphy et al. (1992) showed that the hypoplastic spleens have normal proportions of B and T cell subsets, but exhibit a profound deficiency of immature B cells in bone marrow. Treatment with human GH increased the number of splenic B, CD4 + and CD8 + cells but did not reconstitute the missing immature B cell compartment in bone marrow. We show that IGF-II transgenic dwarf mice exhibit an increased number of thymocytes and CD4
+ splenocytes compared with control dwarf mice. This increase was identical to that found in normal IGF-II transgenic FVB/N mice. On the other hand, there was no significant effect on the number of mature B cells in bone marrow and spleen, although the total number of nucleated bone marrow and immature B cells was increased.
Materials and Methods

Reagents
Fluorescein isothiocyanate (FITC)-conjugated anti-CD3 and phycoerythrin (PE)-conjugated B220 were obtained from Pharmingen (San Diego, CA, USA). FITCconjugated anti-mouse IgM was purchased from Nordic (Tilburg, The Netherlands) and PE-conjugated-anti-CD4 (L3T4) and biotinylated-anti-CD8 (Ly2) were obtained from Becton Dickinson (Mountain View, CA, USA). Tricolor-conjugated streptavidin was purchased from Caltag (San Francisco, CA, USA).
Mice
IGF-II transgenic dwarf mice were obtained by intercrossing Snell dwarf males (dw/dw) with females from an FVB/N mouse line (5 -74) which expresses human IGF-II under the control of the H2K promoter (van Buul-Offers et al. 1995) . The resulting transgenic dwarf mice (dw/dw IGF-IItg) were compared with control dwarf mice that were obtained by intercrossing Snell dwarf males with FVB/N females (dw/dw FVB/N). Normal values were obtained from four 3-week-old non-transgenic FVB/N mice (FVB/N) and four heterozygous Snell mice (dw/+) of the same age. Mice were kept under standardized laboratory conditions as described earlier (van Buul-Offers et al. 1986 ). The 8-week-old mice were all males (n=5 for dw/dw FVB/N; n=8 for dw/dw IGF-IItg). Since the standard deviations in 3-week-old mice were higher compared with adult mice, we used both males and females, in a 1:1 ratio (n=16 for dw/ dw FVB/N; n=10 for dw/dw IGF-IItg). The effects of IGF-II in transgenic males and females were comparable and the data were combined. The protocol received ethical review board approval of the Committee for Animal Experiments of the Medical Faculty, University of Utrecht.
Cell preparations
Mice were killed by decapitation after ether anesthesia. Thymus and spleen were cut into small pieces in Hank's balanced salt solution containing 3% BSA and pressed against a stainless mesh to obtain single-cell suspensions. Subsequently, thymocytes were washed twice in minimal essential medium (MEM). Erythrocytes in single-cell suspensions from spleen were removed by hypotonic shock and two washing steps in MEM. Suspensions of bone marrow cells were prepared from femora and tibiae in Hank's balanced salt solution supplemented with 5% fetal calf serum (FCS). The bones were cleaned of muscles and tendons and then ground in a mortar. Single cell suspensions were obtained by aspiration through a 21 gauge needle. The number of nucleated cells was determined by counting an aliquot stained with Türk's solution in a Bürker-Türk counting chamber.
Fluorescent antibody staining
For immunofluorescence staining of thymocytes and splenocytes, 0·5 10 6 cells suspended in 10 µl MEM containing 1% BSA and 0·02% azide (MEM/BSA/azide) were incubated at 5 C for 30 min with a mixture of PE-anti-CD4 and biotinylated anti-CD8. Subsequently, the cells were washed twice in MEM/BSA/azide at 5 C and incubated with FITC-anti-CD3 and Tricolorconjugated streptavidin at 5 C for 30 min, and washed. Mature splenic B cells and immature B cells in isolated bone marrow cells were stained in a one-step labeling reaction with FITC-labeled IgM and PE-conjugated B220.
Flow cytometry
Cells after immunolabeling were analyzed on a FACStar flow cytometer (Becton Dickinson, Mountain View, CA, USA) equipped with an argon laser (488 nm excitation) and appropriate filter settings for FITC, PE and Tricolor fluorescence examination. For each sample forward light scatter, side scatter, green fluorescence (FITC), red fluorescence (PE) and far-red fluorescence (Tricolor) signals were acquired in list mode. The spectral overlap of the different fluorescence emission spectra was corrected by electronic compensation. Debris, death cells and stromal cells from the thymus were excluded by gating on the basis of forward and site scatter.
Statistical analysis
All data are presented as means ... The significance of observed differences between two groups was determined using Student's t-test.
Results
Thymic cellularity and the presence of different developmental stages
The thymus of 3-week-old control dwarf mice (dw/dw FVB/N) contained significantly less thymocytes than those of heterozygous Snell mice (dw/+) and FVB/N mice (Fig. 1a) . A similar reduction in thymocyte number was observed in 8-week-old dwarf mice (data not shown). IGF-II transgenic dwarf mice (dw/dw IGF-IItg) had more thymocytes than control dwarf mice. However, the difference only reached significance in 8-week-old mice (Fig. 1a) . On the other hand, the body weight and length of the transgenic dwarf mice were identical to those in control dwarf mice (data not shown).
Murine (Guidos et al. 1989a,b) . To address T cell development we determined the number of mature thymocytes with tricolor flow cytometry using antibodies against CD3, CD4 and CD8. It appeared that the number of mature CD3 ++ CD4 + CD8 thymocytes was significantly higher in 3-and 8-week-old transgenic dwarf mice compared with control dwarf mice (Fig. 1b) . At 3 weeks of age, the number of CD3 ++ CD4 + CD8 cells was almost the same as the number in heterozygous Snell mice and FVB/N mice. In contrast, the number of CD3 ++ CD4 CD8 + cells was not changed in IGF-II transgenic dwarf mice (Fig. 1c) .
To further address the differential effects of IGF-II on the development of single positive CD4 + or CD8 + T cells, we also determined the proportions of different thymocyte subsets. 
Lymphocyte number and phenotype of spleen cells
The effects of IGF-II on the number of splenocytes were assessed in 3-and 8-week-old transgenic dwarf mice. Similar to the thymus, the splenic cellularity in dwarf mice (dw/dw FVB/N) was markedly reduced compared with heterozygous Snell mice (dw/+) and FVB/N mice ( Fig. 2A) . At 3 weeks of age, the number of splenocytes in IGF-II transgenic dwarf mice (dw/dw IGF-IItg) was significantly higher compared with control dwarf mice (dw/dw FVB/N), while at 8 weeks, the number of splenocytes in IGF-II transgenic dwarf mice was equal to that in control dwarfs.
The number of CD4 + (helper) T cells in the spleen of IGF-II transgenic dwarf mice was significantly increased at both 3 and 8 weeks of age (Fig. 2b) , whereas the number of CD8 + (suppressor/cytotoxic) cells was increased at 3 weeks of age only (Fig. 2c) . Statistically significant effects on numbers of splenic B cells (IgM + ) were not found (Fig. 2d) . Three-week-old IGF-II transgenic dwarf mice were still hypoplastic compared with both control strains showing a reduced splenic weight (data not shown), a reduced number of splenocytes ( Fig. 2a; P<0·03) and a reduced number of B cells ( Fig. 2d; P<0·01) . In contrast, the number of both CD4 + and CD8 + T cell subsets was not significantly reduced ( Fig. 2b and c) .
The stage of maturity of the CD4 + and CD8 + T cells in the spleen was determined by three-color staining with CD3 as a marker for mature cells. It appeared that 90-98% of both the CD4 + and the CD8 + T cells expressed CD3, and that CD3 expression was not influenced by IGF-II (data not shown). Furthermore, we found that the fraction of immature double-positive (CD4 + CD8 + ) T cells in the spleen of all mice tested varied from 1 to 2%. There were no significant differences in the percentage of CD4 + CD8 + T cells in IGF-II transgenic and control dwarf mice (data not shown).
Bone marrow white blood cells
To address the possible effects of IGF-II on B cell development in more detail, we assessed the number of mature B cells (B220 + /IgM + ) and immature B cells (B220 + /IgM ) in bone marrow. In the 3-week-old transgenic dwarf mice we found a 70% increase in the total number of nucleated bone marrow cells and a 58% increase in the number of immature (B220 + IgM ) B cells ( Fig. 3a and b) . However, the number of mature B cells (B220 + IgM + ) was not significantly increased (Fig. 3c) .
Discussion
Earlier we studied the in vivo effects of IGF-II in transgenic mice that overexpress human IGF-II under the control of the H2K promoter. Body length and total weight of transgenic mice as a function of age were not different from controls. The thymus was the only organ whose weight was increased in transgenic mice (van Buul-Offers et al. 1995) . Overexpression of IGF-II increased thymic cellularity and stimulated the generation of phenotypically normal T cells with a preference to CD4 + cells, whereas B cell development was not influenced (Kooijman et al. 1995b) .
In the present study, we show that the effects of IGF-II on T cell development in transgenic dwarf mice are similar to those in normal transgenic mice. Like in the IGF-II transgenic FVB/N lines, the IGF-II transgenic dwarf mice showed increased numbers of thymocytes and CD4 + T cells in spleen. Furthermore, in both transgenic lines, we found a preferential increase in mature CD4 + CD8 thymocytes compared with CD4 CD8 + thymocytes, and no increase in splenic B cells and CD8 + T cells. These results and the finding that the increases in thymocyte and CD4 + T cell number were not higher in IGF-II transgenic dwarf mice, implies that IGF-I levels do not interfere with the actions of IGF-II on lymphocyte development in mice.
IGF-II transgenic dwarf mice show an increased number of nucleated cells and immature B cells (B220 + IgM ) in bone marrow. This result implies that IGF-II in transgenic mice exerts effects at bone marrow cells. This can be due to either increased levels of IGF-II in serum (van Buul-Offers et al. 1995) or in bone marrow (personal communication Dr J G Koster, Department of Endocrinology, University Hospital for Children and Youth, Utrecht, The Netherlands). However, like in spleen, the number of mature B cells in bone marrow was not increased. The lack of IGF-II effects on B cell development in dwarf mice which express low concentrations of IGF-I is a strong argument for the hypothesis that IGF-II cannot stimulate the development of mature B cells in vivo. However, dwarf mice are also deficient in GH which might work synergistically with IGF-II. Therefore, we tested whether IGF-II could stimulate B cell development in 8-week-old dwarf mice that were treated with human GH for 4 weeks (three injections with 5·5 mU GH per day). We found that the number of splenic T cells was increased by 89% (P<0·03) from 7·3 10 6 to 14·0 10 6 , whereas the number of B cells decreased slightly from 15·1 10 6 to 13·0 10 6 (not significant). Thus, overexpression of IGF-II does not influence B cell development in GH-treated dwarf mice.
In another transgenic model, IGF-II was placed under the control of the rat phosphoenolpyruvate carboxykinase promoter (Wolf et al. 1994) . Transgenic-specific transcripts were found in the liver, kidney and several parts of the gut, and serum levels of IGF-II were increased. In these mice, however, the weight of the thymus was not affected. Possibly, the high levels of IGF-II in the thymus of the IGF-II transgenic mice (van Buul-Offers et al. 1995 , van der Ven et al. 1997 are essential for the effects on thymic growth. Autocrine or paracrine effects of IGF-II in T cell development in human and rodents can be expected as suggested by the expression of IGF-II transcripts (Brown et al. 1986 ) and peptides (Nagaoka et al. 1990 , Geenen et al. 1993 in the thymus.
Unlike IGF-II, IGF-I stimulates B cell development in vivo (Clark et al. 1993 ). This finding is consistent with in vitro effects of IGF-I and IGF-II on pro-B cells. Gibson et al. (1993) showed that IGF-II was a less potent stimulator of IL-7 dependent proliferation of pro-B cells than IGF-I and proposed that IGF-II is probably not an important regulator of B cell development. On the other hand, the stimulating effects of IGF-II on T cell development are in accordance with our finding that IGF-II is a very potent stimulator of DNA synthesis in murine thymocytes. We also showed that IGF-II is a more potent stimulator of thymocyte proliferation than IGF-I (Kooijman et al. 1995b) . At the cellular level, the differences between thymocytes and pro-B cells can be explained by the differential expression of type II IGF receptors. Rat thymocytes and murine thymoma cells express functional type II IGF receptors (Verland & Gammeltoft 1989) , whereas murine pro-B cells were found to express the type I IGF receptor transcripts but not the mRNA for type II receptors (Gibson et al. 1993) . Further research on the effects of IGFs on lymphopoiesis is necessary to assess whether IGF-II specifically stimulates T cell development via the type II IGF receptor, and whether the effects are mediated by other cytokines (e.g. IL-7). A functional role for type II IGF receptors opens up the possibility that IGF-II is the dominant factor in T cell development with a facultative role for IGF-I. In this model, the levels of the respective IGF receptors in different tissues would determine the response to IGF-I and IGF-II.
